Search

Displaying results 2141 - 2150 of 7687 in total
  1. Drug

    Brodalumab

    go.drugbank.com/drugs/DB11776
    ApprovedInvestigational

    Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

  2. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis. … Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s.

  3. Drug

    Phenyl salicylate

    go.drugbank.com/drugs/DB11071
    Approved

    It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure

    Mixtures: Urin D/S, Prosed/DS
  4. Drug

    Cyclizine

    go.drugbank.com/drugs/DB01176
    ApprovedWithdrawn

    A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)

  5. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474] … KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs).

  6. Drug

    Fesoterodine

    go.drugbank.com/drugs/DB06702
    Approved

    Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

  7. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly. … Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  8. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients. … Etuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo.

  9. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology

  10. Drug

    Taurolidine

    go.drugbank.com/drugs/DB12473
    ApprovedInvestigational

    Taurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid [taurine]. … [A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial